PURPOSE: To assess the impact of weight loss on health-related quality-of-life (HRQL), to describe the factors associated with improvements in HRQL after weight loss, and to assess the relationship between obesity as assessed by body mass index (BMI) and HRQL before and after weight loss. METHODS: We studied 188 obese patients with BMI ≥ 32 kg/m(2) with one or more comorbidities or ≥35 kg/m(2). All patients had baseline and follow-up assessments of BMI and HRQL using the EuroQol (EQ-5D) and its visual analog scale (VAS) before and after 6 months of medical weight loss that employed very low-calorie diets, physical activity, and intensive behavioral counseling. RESULTS: At baseline, age was 50 ± 8 years (mean ± SD), BMI was 40. 0 ± 5.0 kg/m(2), EQ-5D-derived health utility score was 0.85 ± 0.13, and VAS-reported quality-of-life was 0.67 ± 0.18. At 6-month follow-up, BMI decreased by 7.0 ± 3.2 kg/m(2), EQ-5D increased by 0.06 [interquartile range (IQR) 0.06-0.17], and VAS increased by 0.14 (IQR 0.04-0.23). In multivariate analyses, improvement in EQ-5D and VAS were associated with lower baseline BMI, greater reduction in BMI at follow-up, fewer baseline comorbidities, and lower baseline HRQL. For any given BMI category, EQ-5D and VAS tended to be higher at follow-up than at baseline. CONCLUSION: Measured improvements in HRQL between baseline and follow-up were greater than predicted by the reduction in BMI at follow-up. If investigators use cross-sectional data to estimate changes in HRQL as a function of BMI, they will underestimate the improvement in HRQL associated with weight loss and underestimate the cost-utility of interventions for obesity treatment.
PURPOSE: To assess the impact of weight loss on health-related quality-of-life (HRQL), to describe the factors associated with improvements in HRQL after weight loss, and to assess the relationship between obesity as assessed by body mass index (BMI) and HRQL before and after weight loss. METHODS: We studied 188 obesepatients with BMI ≥ 32 kg/m(2) with one or more comorbidities or ≥35 kg/m(2). All patients had baseline and follow-up assessments of BMI and HRQL using the EuroQol (EQ-5D) and its visual analog scale (VAS) before and after 6 months of medical weight loss that employed very low-calorie diets, physical activity, and intensive behavioral counseling. RESULTS: At baseline, age was 50 ± 8 years (mean ± SD), BMI was 40. 0 ± 5.0 kg/m(2), EQ-5D-derived health utility score was 0.85 ± 0.13, and VAS-reported quality-of-life was 0.67 ± 0.18. At 6-month follow-up, BMI decreased by 7.0 ± 3.2 kg/m(2), EQ-5D increased by 0.06 [interquartile range (IQR) 0.06-0.17], and VAS increased by 0.14 (IQR 0.04-0.23). In multivariate analyses, improvement in EQ-5D and VAS were associated with lower baseline BMI, greater reduction in BMI at follow-up, fewer baseline comorbidities, and lower baseline HRQL. For any given BMI category, EQ-5D and VAS tended to be higher at follow-up than at baseline. CONCLUSION: Measured improvements in HRQL between baseline and follow-up were greater than predicted by the reduction in BMI at follow-up. If investigators use cross-sectional data to estimate changes in HRQL as a function of BMI, they will underestimate the improvement in HRQL associated with weight loss and underestimate the cost-utility of interventions for obesity treatment.
Authors: ShanKuan Zhu; ZiMian Wang; Stanley Heshka; Moonseong Heo; Myles S Faith; Steven B Heymsfield Journal: Am J Clin Nutr Date: 2002-10 Impact factor: 7.045
Authors: M F Janssen; A Simon Pickard; Dominik Golicki; Claire Gudex; Maciej Niewada; Luciana Scalone; Paul Swinburn; Jan Busschbach Journal: Qual Life Res Date: 2012-11-25 Impact factor: 4.147
Authors: Ivana T Croghan; Ryan T Hurt; Darrell R Schroeder; Shawn C Fokken; Michael D Jensen; Matthew M Clark; Jon O Ebbert Journal: Lasers Med Sci Date: 2019-08-31 Impact factor: 3.161
Authors: Paul Brunault; Julie Frammery; Charles Couet; Irène Delbachian; Céline Bourbao-Tournois; Martine Objois; Patricia Cosson; Christian Réveillère; Nicolas Ballon Journal: Qual Life Res Date: 2014-08-12 Impact factor: 4.147
Authors: Chanisa Thonusin; Heidi B IglayReger; Tanu Soni; Amy E Rothberg; Charles F Burant; Charles R Evans Journal: J Chromatogr A Date: 2017-09-09 Impact factor: 4.759
Authors: Kristen M Ward; Larisa Yeoman; Cora McHugh; A Zarina Kraal; Stephanie A Flowers; Amy E Rothberg; Alla Karnovsky; Arun K Das; Vicki L Ellingrod; Kathleen A Stringer Journal: Pharmacotherapy Date: 2018-06 Impact factor: 4.705
Authors: Kavita Singh; Dimple Kondal; Roopa Shivashankar; Mohammed K Ali; Rajendra Pradeepa; Vamadevan S Ajay; Viswanathan Mohan; Muhammad M Kadir; Mark Daniel Sullivan; Nikhil Tandon; K M Venkat Narayan; Dorairaj Prabhakaran Journal: BMJ Open Date: 2017-10-15 Impact factor: 2.692